Droperidol and Muscle weakness aggravated for Women aged 50-59 (a phase IV clinical study of FDA data)

Summary:

Muscle weakness aggravated is found for women aged 50-59 who take Droperidol (droperidol). This study is created by eHealthMe based on reports of 203 women aged 50-59 from the FDA, and is updated regularly. The information that eHealthMe analyzes includes:

  • Time on Droperidol when people have Muscle weakness aggravated
  • Top conditions
  • Top co-used drugs
  • Top other side effects


On Mar, 25, 2026

203 women aged 50-59 reported to have side effects when taking Droperidol.
Among them, 11 people (5.42%) have Muscle weakness aggravated


What is Droperidol?

Droperidol has active ingredients of droperidol. eHealthMe is studying from 2,452 Droperidol users. Check the latest studies of Droperidol.

What is Muscle weakness aggravated?

Muscle weakness aggravated (lack of muscle strength) is found to be associated with 2,305 drugs and 894 conditions by eHealthMe. Check the latest studies of Muscle weakness aggravated.

Number of reports submitted per year:

Could Droperidol cause Muscle weakness aggravated in women aged 50-59?

Severity of Muscle weakness aggravated

n/a

How people recovered from Muscle weakness aggravated

n/a

Top conditions involved for these people *:

You may use this to check any potential undetected conditions.

  1. Neuromuscular Blockade Reversal: 1 person, 9.09%
  2. Multiple Myeloma (cancer of the plasma cells): 1 person, 9.09%
  3. Breast Cancer: 1 person, 9.09%
  4. Bone Disorder: 1 person, 9.09%

Top co-used drugs for these people *:

You may use this to check any potential interacting drugs.

  1. Lasix: 9 people, 81.82%
  2. Keflex: 8 people, 72.73%
  3. Aranesp: 8 people, 72.73%
  4. Neurontin: 8 people, 72.73%
  5. Zometa: 8 people, 72.73%
  6. Lortab: 8 people, 72.73%
  7. Fentanyl Citrate: 8 people, 72.73%
  8. Percocet: 8 people, 72.73%
  9. Neostigmine Methylsulfate: 7 people, 63.64%
  10. Midazolam Hydrochloride: 7 people, 63.64%

Top other side effects for these people *:

You may use this to check any potential undetected side effects.

  1. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 9 people, 81.82%
  2. Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 8 people, 72.73%
  3. Cardiomyopathy (weakening of the heart muscle): 8 people, 72.73%
  4. Osteonecrosis Of Jaw (death of bone of jaw): 8 people, 72.73%
  5. Cellulitis (infection under the skin): 8 people, 72.73%
  6. Chronic Renal Failure (kidney failure): 8 people, 72.73%
  7. Haemangioma (noncancerous, abnormally dense collections of dilated small blood vessels that may occur in the skin or internal organs): 8 people, 72.73%
  8. Neuropathy Peripheral (surface nerve damage): 8 people, 72.73%
  9. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 8 people, 72.73%
  10. Deformity (disfigurement): 8 people, 72.73%

* Approximation only. Some reports may have incomplete information.

Do you take Droperidol and have Muscle weakness aggravated?

- Check whether Muscle weakness aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.



Related studies:

How the study uses the data?

The study is based on (applicable) gender, age, droperidol (the active ingredients of Droperidol) and Droperidol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: